MX2020001178A - Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos. - Google Patents
Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos.Info
- Publication number
- MX2020001178A MX2020001178A MX2020001178A MX2020001178A MX2020001178A MX 2020001178 A MX2020001178 A MX 2020001178A MX 2020001178 A MX2020001178 A MX 2020001178A MX 2020001178 A MX2020001178 A MX 2020001178A MX 2020001178 A MX2020001178 A MX 2020001178A
- Authority
- MX
- Mexico
- Prior art keywords
- cas
- human animals
- methods
- crispr
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Abstract
En la presente se proporcionan los métodos y las composiciones para evaluar la actividad de la unión de los extremos no homólogos (NHEJ) mediada por CRISPR/Cas y/o de la recombinación inducida por CRISPR/Cas de un locus genómico objetivo con un ácido nucleico donador exógeno in vivo y ex vivo. Los métodos y las composiciones emplean células y animales no humanos que comprenden un casete de expresión de Cas, tal como un casete de expresión de Cas genómicamente integrado de una manera tal que la proteína Cas puede estar constitutivamente disponible o disponible de una manera específica del tejido o específica del tiempo. También se proporcionan los métodos y las composiciones para hacer y usar estos animales no humanos, con la inclusión del uso de estos animales no humanos para evaluar la actividad de CRISPR/Cas in vivo por medio del suministro mediado por el virus adeno-asociado (AAV) de los ARNs de guía a los animales no humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539275P | 2017-07-31 | 2017-07-31 | |
PCT/US2018/044615 WO2019028032A1 (en) | 2017-07-31 | 2018-07-31 | EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001178A true MX2020001178A (es) | 2020-09-25 |
Family
ID=63350596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001178A MX2020001178A (es) | 2017-07-31 | 2018-07-31 | Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (3) | US11130999B2 (es) |
EP (1) | EP3585159A1 (es) |
JP (2) | JP7359753B2 (es) |
KR (1) | KR20200032693A (es) |
CN (2) | CN115074343A (es) |
AU (1) | AU2018309716A1 (es) |
BR (1) | BR112020001364A2 (es) |
CA (1) | CA3067872A1 (es) |
IL (1) | IL272334A (es) |
MX (1) | MX2020001178A (es) |
SG (1) | SG11201912235PA (es) |
WO (1) | WO2019028032A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020001364A2 (pt) | 2017-07-31 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | métodos para testar e modificar a capacidade de uma crispr/cas nuclease. |
EP3769090B1 (en) | 2019-03-18 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation |
WO2020190932A1 (en) | 2019-03-18 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation |
CA3133361A1 (en) | 2019-04-03 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
WO2020236597A1 (en) * | 2019-05-17 | 2020-11-26 | Massachusetts Institute Of Technology | Engineered post-poly a signal rna and uses thereof |
US11845957B2 (en) | 2019-06-14 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Models of tauopathy |
CN114746125A (zh) | 2019-11-08 | 2022-07-12 | 瑞泽恩制药公司 | 用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略 |
US20210274759A1 (en) | 2020-03-04 | 2021-09-09 | Regeneron Pharmaceuticals, Inc. | A rodent model of b4galt1-mediated functions |
EP4352519A1 (en) * | 2021-05-20 | 2024-04-17 | Synteny Therapeutics, Inc. | Genomic safe harbors |
CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
WO2023212616A2 (en) * | 2022-04-27 | 2023-11-02 | Alpha Teknova, Inc. | Detection, quantification, and expression analysis of full viral capsids |
WO2023220603A1 (en) * | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
CN115992178A (zh) * | 2022-08-08 | 2023-04-21 | 首都医科大学附属北京天坛医院 | 核心蛋白聚糖转基因小鼠的制备方法及应用 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
AU8587598A (en) | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
CA2474486C (en) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US20080131962A1 (en) | 2006-05-25 | 2008-06-05 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
KR20070060115A (ko) | 2004-09-16 | 2007-06-12 | 상가모 바이오사이언스 인코포레이티드 | 단백질 생산을 위한 조성물 및 방법 |
AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
JP5551432B2 (ja) | 2006-05-25 | 2014-07-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 遺伝子不活性化のための方法と組成物 |
JP4692417B2 (ja) | 2006-06-30 | 2011-06-01 | 富士ゼロックス株式会社 | 画像形成装置 |
CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
WO2008133938A2 (en) | 2007-04-26 | 2008-11-06 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
WO2008149176A1 (en) | 2007-06-06 | 2008-12-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof |
KR20100120226A (ko) | 2008-04-11 | 2010-11-12 | 유티씨 파워 코포레이션 | 매니폴드 섬프를 갖는 바이폴라 플레이트 및 연료 전지 |
KR101880536B1 (ko) | 2010-04-26 | 2018-07-23 | 상가모 테라퓨틱스, 인코포레이티드 | 아연 핑거 뉴클레아제를 사용하는 로사 좌위의 게놈 편집 |
AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
JP6185916B2 (ja) | 2011-09-21 | 2017-08-23 | サンガモ セラピューティクス, インコーポレイテッド | 導入遺伝子発現を制御するための方法および組成物 |
EP2771457B1 (en) | 2011-10-27 | 2017-11-22 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the hprt locus |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
CA2869016C (en) | 2012-04-25 | 2020-05-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
LT2800811T (lt) | 2012-05-25 | 2017-09-11 | The Regents Of The University Of California | Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr |
WO2014033644A2 (en) | 2012-08-28 | 2014-03-06 | Novartis Ag | Methods of nuclease-based genetic engineering |
KR101656237B1 (ko) | 2012-10-23 | 2016-09-12 | 주식회사 툴젠 | 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도 |
PL3138910T3 (pl) | 2012-12-06 | 2018-01-31 | Sigma Aldrich Co Llc | Oparta na CRISPR modyfikacja i regulacja genomu |
IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
MX2015007743A (es) | 2012-12-17 | 2015-12-07 | Harvard College | Ingenieria del genoma humano guiada por ácido robonucleico. |
SG10201706741VA (en) | 2013-02-20 | 2017-10-30 | Regeneron Pharma | Genetic modification of rats |
EP2922393B2 (en) | 2013-02-27 | 2022-12-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
WO2014144592A2 (en) | 2013-03-15 | 2014-09-18 | The General Hospital Corporation | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
CN105518146B (zh) | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
BR112015026197B1 (pt) | 2013-04-16 | 2022-12-06 | Regeneron Pharmaceuticals, Inc | Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente |
EP3778899A1 (en) | 2013-05-22 | 2021-02-17 | Northwestern University | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
EP3620524A1 (en) | 2013-06-17 | 2020-03-11 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
CN113425857A (zh) | 2013-06-17 | 2021-09-24 | 布罗德研究所有限公司 | 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途 |
CN106222197A (zh) | 2013-07-16 | 2016-12-14 | 中国科学院上海生命科学研究院 | 植物基因组定点修饰方法 |
US11306328B2 (en) | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
TW201542816A (zh) | 2013-09-18 | 2015-11-16 | Kymab Ltd | 方法、細胞與生物體 |
KR102370419B1 (ko) | 2013-09-23 | 2022-03-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물 |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
US9957526B2 (en) | 2013-10-17 | 2018-05-01 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
RU2725520C2 (ru) | 2013-12-11 | 2020-07-02 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
WO2015127439A1 (en) | 2014-02-24 | 2015-08-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration |
CA3194412A1 (en) | 2014-02-27 | 2015-09-03 | Monsanto Technology Llc | Compositions and methods for site directed genomic modification |
CN103911376B (zh) * | 2014-04-03 | 2017-02-15 | 黄行许 | CRISPR‑Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA |
WO2015179540A1 (en) | 2014-05-20 | 2015-11-26 | Regents Of The University Of Minnesota | Method for editing a genetic sequence |
WO2015191693A2 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
CN114686483A (zh) | 2014-06-16 | 2022-07-01 | 约翰斯·霍普金斯大学 | 用于使用h1启动子表达crispr向导rna的组合物和方法 |
DK3155099T3 (en) | 2014-06-23 | 2018-05-07 | Regeneron Pharma | NUCLEASE MEDIATED DNA COLLECTION |
US20150376586A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
CA3172866A1 (en) | 2014-06-26 | 2015-12-30 | Regeneron Pharamaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
EP2966170A1 (en) | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
ES2949172T3 (es) | 2014-07-16 | 2023-09-26 | Novartis Ag | Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas |
CN104178461B (zh) * | 2014-08-14 | 2017-02-01 | 北京蛋白质组研究中心 | 携带cas9的重组腺病毒及其应用 |
US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
WO2016049024A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016049163A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
CN107429246B (zh) | 2014-10-31 | 2021-06-01 | 麻省理工学院 | 用于crispr的大规模并行组合遗传学 |
CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
KR20230070319A (ko) | 2014-11-21 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
WO2016089866A1 (en) | 2014-12-01 | 2016-06-09 | President And Fellows Of Harvard College | Rna-guided systems for in vivo gene editing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
CN104498493B (zh) * | 2014-12-30 | 2017-12-26 | 武汉大学 | CRISPR/Cas9特异性敲除乙型肝炎病毒的方法以及用于特异性靶向HBV DNA的gRNA |
CN107406842B (zh) | 2015-01-09 | 2021-05-11 | 生物辐射实验室股份有限公司 | 检测基因组编辑 |
CN107429263A (zh) | 2015-01-15 | 2017-12-01 | 斯坦福大学托管董事会 | 调控基因组编辑的方法 |
WO2016123514A1 (en) | 2015-01-29 | 2016-08-04 | University Of Massachusetts | Nanoparticle-protein complex for intracellular protein delivery |
WO2016132122A1 (en) | 2015-02-17 | 2016-08-25 | University Of Edinburgh | Assay construct |
EP3262162A4 (en) | 2015-02-23 | 2018-08-08 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
US20180110877A1 (en) | 2015-04-27 | 2018-04-26 | The Trustees Of The University Of Pennsylvania | DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
EP3159407A1 (en) | 2015-10-23 | 2017-04-26 | Silence Therapeutics (London) Ltd | Guide rnas, methods and uses |
WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
JP6700306B2 (ja) | 2015-12-18 | 2020-05-27 | 国立研究開発法人科学技術振興機構 | 受精前の卵細胞、受精卵、及び標的遺伝子の改変方法 |
CN105647968B (zh) | 2016-02-02 | 2019-07-23 | 浙江大学 | 一种CRISPR/Cas9工作效率快速测试系统及其应用 |
CN117731805A (zh) | 2016-03-30 | 2024-03-22 | 因特利亚治疗公司 | 用于crispr/cas成分的脂质纳米颗粒制剂 |
WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
GB201619876D0 (en) | 2016-11-24 | 2017-01-11 | Cambridge Entpr Ltd | Controllable transcription |
BR112019011509A2 (pt) | 2016-12-08 | 2020-01-28 | Intellia Therapeutics Inc | rnas guias modificados |
AU2017374042B2 (en) | 2016-12-09 | 2024-02-15 | Acuitas Therapeutics, Inc. | Delivery of target specific nucleases |
CN110582302A (zh) | 2016-12-14 | 2019-12-17 | 利甘达尔股份有限公司 | 用于核酸和/或蛋白有效负载递送的组合物和方法 |
WO2018132936A1 (en) | 2017-01-17 | 2018-07-26 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Genetical alternation and disease modelling using cre-dependent cas9 expressing mammals |
BR112020001364A2 (pt) | 2017-07-31 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | métodos para testar e modificar a capacidade de uma crispr/cas nuclease. |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
KR20210029772A (ko) | 2018-06-08 | 2021-03-16 | 인텔리아 테라퓨틱스, 인크. | 유전자 편집을 위한 변형된 가이드 rna |
EP3810148A4 (en) | 2018-06-19 | 2022-06-08 | The Board Of Regents Of The University Of Texas System | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING MRNA AND LONG NUCLEIC ACIDS |
-
2018
- 2018-07-31 BR BR112020001364-1A patent/BR112020001364A2/pt unknown
- 2018-07-31 KR KR1020207001973A patent/KR20200032693A/ko not_active Application Discontinuation
- 2018-07-31 WO PCT/US2018/044615 patent/WO2019028032A1/en unknown
- 2018-07-31 SG SG11201912235PA patent/SG11201912235PA/en unknown
- 2018-07-31 US US16/050,784 patent/US11130999B2/en active Active
- 2018-07-31 EP EP18759200.1A patent/EP3585159A1/en active Pending
- 2018-07-31 CN CN202210528912.0A patent/CN115074343A/zh active Pending
- 2018-07-31 AU AU2018309716A patent/AU2018309716A1/en active Pending
- 2018-07-31 CN CN201880044435.2A patent/CN110891420B/zh active Active
- 2018-07-31 MX MX2020001178A patent/MX2020001178A/es unknown
- 2018-07-31 JP JP2020504684A patent/JP7359753B2/ja active Active
- 2018-07-31 CA CA3067872A patent/CA3067872A1/en active Pending
-
2020
- 2020-01-29 IL IL272334A patent/IL272334A/en unknown
-
2021
- 2021-08-24 US US17/410,437 patent/US11866794B2/en active Active
-
2023
- 2023-09-28 JP JP2023168417A patent/JP2023165953A/ja active Pending
- 2023-11-27 US US18/520,007 patent/US20240093316A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023165953A (ja) | 2023-11-17 |
US20190032155A1 (en) | 2019-01-31 |
AU2018309716A1 (en) | 2020-01-16 |
RU2020105343A3 (es) | 2021-11-11 |
BR112020001364A2 (pt) | 2020-08-11 |
US11866794B2 (en) | 2024-01-09 |
KR20200032693A (ko) | 2020-03-26 |
CN110891420B (zh) | 2022-06-03 |
CA3067872A1 (en) | 2019-02-07 |
SG11201912235PA (en) | 2020-01-30 |
CN115074343A (zh) | 2022-09-20 |
US20210392862A1 (en) | 2021-12-23 |
WO2019028032A1 (en) | 2019-02-07 |
CN110891420A (zh) | 2020-03-17 |
IL272334A (en) | 2020-03-31 |
JP2020532952A (ja) | 2020-11-19 |
EP3585159A1 (en) | 2020-01-01 |
RU2020105343A (ru) | 2021-09-02 |
JP7359753B2 (ja) | 2023-10-11 |
US20240093316A1 (en) | 2024-03-21 |
US11130999B2 (en) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020001178A (es) | Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos. | |
MX2021014368A (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
MX2020001177A (es) | Animales no humanos reporteros de crispr y usos de los mismos. | |
ZA202206102B (en) | Excision of retroviral nucleic acid sequences | |
MX2019012311A (es) | Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso. | |
PH12016502058A1 (en) | Humanized il-4 and il-4r alpha animals | |
TR201806812T4 (tr) | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. | |
RU2017124909A (ru) | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания | |
WO2015164750A3 (en) | Compositions and methods to treating hemoglobinopathies | |
SG10201808935WA (en) | Targeted modification of rat genome | |
MX2016003636A (es) | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. | |
PH12016502170A1 (en) | Humanized dipeptidyl peptidase iv (dpp4) animals | |
MX2017007320A (es) | Generacion de canola transgenica con acidos grasos de baja saturacion o no saturados. | |
MX2021004455A (es) | Composiciones y métodos para administrar transgenes. | |
MX2018009513A (es) | Animales no humanos que tienen un gen angptl8 modificado genéticamente. | |
MX2009006681A (es) | Composiciones y metodos para la expresion de acidos nucleicos. | |
MX2021010611A (es) | Aves con genoma editado. | |
CA2955203C (en) | Nanos knock-out that ablates germline cells | |
EA202090585A1 (ru) | Птицы с отредактированным геномом | |
JP2016527901A5 (es) | ||
WO2018067608A3 (en) | Animal model of angelman syndrome | |
Liao et al. | The Research of Several Problems in the Construction of Jiangxi Rural Scenic Forest | |
Herskin et al. | Can peripheral nerve damage caused by tail docking lead to tail pain later in the life of pigs? | |
TH168457B (th) | วิธีการและองค์ประกอบสำหรับการดัดแปลงที่มีเป้าหมายของจีโนม | |
Ordovas Vidal et al. | Efficient recombinase mediated cassette exchange in hPSC to study the hepatic lineage reveals AAVS1 locus-mediated transgene inhibition |